Navigation Links
Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
Date:11/11/2013

DURHAM, N.C., Nov. 11, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, presented an analysis of data from its Phase 2 clinical trial showing that treatment with AGS-003, the company's lead product candidate, in combination with sunitinib, induced memory T cell responses in metastatic renal cell cancer (mRCC) patients that correlated with statistical significance to overall survival (OS).  The poster, entitled "Multi-Functional Cytotoxic T Cell Expansion Correlates with Overall Survival after Administration of Autologus Dendritic Cell Immunotherapy in Renal Cell Cancer Patients," was presented on November 9 at the 28th Annual Meeting of the Society for Immunotherapy of Cancer in National Harbor, Maryland.

AGS-003, an investigational fully personalized immunotherapy, is designed to elicit an immune response by inducing CD8+CD28+ memory T cells that are known to correlate with improved clinical outcomes. In the Phase 2 trial, the Company monitored the immune responses in 14 evaluable intermediate and poor risk mRCC patients using multi-color flow cytometry. The data were analyzed for correlations between immune responses and survival using an adaptation of the bioinformatics pattern recognition algorithm, Binary Tree-Structured Vector Quantization (BTSVQ). Patients in the trial received treatment in standard six-week cycles of sunitinib plus AGS-003 every three weeks for five doses and then every 12 weeks until progression.  BTSVQ identified unique cytotoxic T cell (CTL) signatures displaying broad markers of immune function (MIFs) that were statistically significant predictors of survival duration as well as mono-functional late-stage effector T cells that inversely correla
'/>"/>

SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
2. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
3. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
4. Convoy Therapeutics Appoints Clinical Advisory Board
5. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
6. United Therapeutics Corporation Reports Third Quarter 2013 Financial Results
7. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
8. Moderna Therapeutics Named to the World Economic Forums Community of "Global Growth Companies"
9. United Therapeutics Corporation to Announce Third Quarter 2013 Financial Results Before Market Open on Tuesday, October 29, 2013
10. PTC Therapeutics Expands Management Team
11. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 27, 2015 Expanding in a big ... Avalon Biomed Inc. recently inked a deal ... Dental Co. Ltd. , the largest endodontic distributor in ... international market for Avalon Biomed, which manufactures Grey MTA ... silicate-based dental cements that have won renown from dentists ...
(Date:5/27/2015)... , May 27, 2015  Tikcro Technologies Ltd. (OTCQB: ... March 31, 2015. Aviv Boim ... continued pre-clinical work to generate functional specific antibodies, targeting ... stage, we are encouraged by the development progress. We ... new antibodies which modulate immune checkpoints gain clinical acceptance ...
(Date:5/27/2015)... Empowering biomedical researchers with richer, more ... today announced its MR Compatible Small Animal PET ... uses silicon photomultiplier detector technology, so it can ... manufacturers like Bruker and Agilent,” said James Schellenberg, ... enables simultaneous PET and MRI data acquisition with ...
(Date:5/27/2015)... , May 27, 2015  Northwest Biotherapeutics, Inc. ... developing DCVax® personalized immune therapies for cancer, announced today ... Officer of the Company, will be making an Industry ... in Chicago on Saturday, May ... the Industry Expert Theater in McCormick Place. ...
Breaking Biology Technology:Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3Cubresa Launches Simultaneous PET/MRI Technology 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3
... Calif., June 5 /PRNewswire-FirstCall/ - BioMarin Pharmaceutical,Inc. (Nasdaq ... its third,enzyme replacement therapy (ERT) for the treatment ... BioMarin plans to initiate a Phase,1/2 clinical trial ... two MPS drugs on the market, we plan ...
... ) notes that FDA has published a notice of a ... to,be held on July 23, 2008. The Committee will address ... " ... presentations from the Office of Generic Drugs (OGD) ... treat gastrointestinal (GI) conditions ... " For over ...
... Will be Presented at the American Society for Mass ... 56th ASMS Conference in Denver, June ... Inc.,(Nasdaq: BNVI ) today announced that it has ... platform that allows for the rapid, specific, sensitive,automated quantification ...
Cached Biology Technology:BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome 2BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome 3BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome 4Viropharma Comments On Upcoming FDA Advisory Committee Meeting 2Viropharma Comments On Upcoming FDA Advisory Committee Meeting 3Bionovo Develops a High Throughput LC-MS/MS Method for Simultaneous Quantification of Multiple Bioactive Compounds 2Bionovo Develops a High Throughput LC-MS/MS Method for Simultaneous Quantification of Multiple Bioactive Compounds 3
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/11/2015)... 11, 2015  Through a well-rounded UAS delegation representing private ... a strong showing at AUVSI,s Unmanned 2015 conference last week ... Ohio,s UAS industry met with over 200 ... points along the UAS ecosystem. "Our message ... President for Aerospace Rich Knoll . "If you want ...
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... Stanley, Inc. (NYSE:,SXE), a leading provider of systems ... announced today that it has entered into a,definitive ... intelligence operations and information technology services,company. The purchase ... to certain working capital and other adjustments as ...
... Calif.) Michael Gazzaniga, professor of psychology at UC ... the Study of the Mind, has received the Humboldt ... "Professor Gazzaniga is a true pioneer in reaching ... the relationship between mind and brain," said UCSB Chancellor ...
... Dozens of instruments to be deployed on the Oak ... provide valuable information related to climate change, biodiversity and ... Walker Branch Watershed and other portions of the ... National Ecological Observatory Network, a multi-decade continental-scale research platform ...
Cached Biology News:Stanley to Acquire Oberon Associates 2Stanley to Acquire Oberon Associates 3Stanley to Acquire Oberon Associates 4Neuroscientist Michael Gazzaniga awarded Humboldt Prize 2Oak Ridge pegged for national ecological network 2
Mouse polyclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = 25797...
... recombinant IFNA2. Immunogen: Human IFNA2 ... in E. coli. The biological activity was ... OMIM: 147562, GeneID: ... MA Code: ABV0P9DPB ...
... longer need to perform time consuming and inaccurate ... Surveyor, any found variants of the sample when ... in our mutation electropherogram as a sharp peak. ... analysis mode is over 99%, with sensitivity to ...
...
Biology Products: